In the SWOG S1613 clinical trial comparing this standard therapy to treatment with two HER2 inhibitors, these patients saw a similar level of clinical benefit, with lower toxicity, from the ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

The oral HER2 inhibitor zongertinib benefited patients with previously treated, HER2-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented by John V ...

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

— HER2 blockade, PARP inhibitors, and other novel strategies by Crystal Phend , Contributing Editor, MedPage Today July 5, 2024 Last Updated August 1, 2024 ...

If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

For breast cancer patients, targeted therapies like HER2 inhibitors have become game-changers. HER2-positive breast cancer, which accounts for about 20% of cases, is particularly aggressive.

ErbB2/HER2 Inhibitors. Mark Slikowski, of Genentech, discussed the methods his group is using to determine which patients are most likely to respond to ErbB2/HER2 inhibitors.